Erythema multiforme-like lesions associated with lesional infiltration of tumor cells occurring with adult T-cell lymphoma/leukemia

2008 ◽  
Vol 47 (4) ◽  
pp. 390-392 ◽  
Author(s):  
Tomoyuki Ohtani ◽  
Masatoshi Deguchi ◽  
Setsuya Aiba
Keyword(s):  
T Cell ◽  
Tumor Cells ◽  
Erythema Multiforme ◽  
Cell Lymphoma ◽  
T Cell Lymphoma

scholarly journals Erythema Multiforme Major in Angioimmunoblastic T-cell Lymphoma

2021 ◽  
Author(s):  
Shoko Hattori ◽  
Fumi Miyagawa ◽  
Keiko Fukuda ◽  
Kohei Ogawa ◽  
Hideo Asada
Keyword(s):  
T Cell ◽  
Erythema Multiforme ◽  
Short Communication ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Erythema Multiforme Major

Abstract is missing (Short communication)

scholarly journals Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

2020 ◽  
Author(s):  
Darci Phillips ◽  
Magdalena Matusiak ◽  
Belén Rivero Gutierrez ◽  
Salil S. Bhate ◽  
Graham L. Barlow ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Clinical Response ◽  
Tumor Cells ◽  
Spatial Organization ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
T Cell Subsets ◽  
Cutaneous T Cell Lymphoma

Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T cell lymphoma (CTCL) patients enrolled in a clinical trial of pembrolizumab therapy. Clinical response was not associated with the frequency of tumor-infiltrating T cell subsets, but rather with striking differences in the spatial organization and functional immune state of the tumor microenvironment (TME). After treatment, pembrolizumab responders had a localized enrichment of tumor and CD4+ T cells, which coincided with immune activation and cytotoxic PD-1+ CD4+ T cells. In contrast, non-responders had a localized enrichment of Tregs pre- and post-treatment, consistent with a persistently immunosuppressed TME and exhausted PD-1+ CD4+ T cells. Integrating these findings by computing the physical distances between PD-1+ CD4+ T cells, tumor cells, and Tregs revealed a spatial biomarker predictive of pembrolizumab response. Finally, the chemokine CXCL13 was upregulated in tumor cells in responders post-treatment, suggesting that chemoattraction of PD-1+ CD4+ T cells towards tumor cells facilitates a positive outcome. Together, these data show that T cell topography reflects the balance of effector and suppressive activity within the TME and predicts clinical response to PD-1 blockade in CTCL.

Erythema multiforme-like cutaneous lesions in monomorphic epitheliotropic intestinal T-cell lymphoma: a rare case report

2016 ◽  
Vol 44 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Kumpol Aiempanakit ◽  
Chitiarpa Amatawet ◽  
Kanokphorn Chiratikarnwong ◽  
Sauvarat Auepemkiate ◽  
Kanita Kayasut ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Erythema Multiforme ◽  
Rare Case ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous Lesions ◽  
Rare Case Report

scholarly journals Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155

2017 ◽  
Vol 137 (8) ◽  
pp. 1766-1773 ◽  
Author(s):  
Naomi Takahashi ◽  
Makoto Sugaya ◽  
Hiraku Suga ◽  
Tomonori Oka ◽  
Makiko Kawaguchi ◽  
...  
Keyword(s):  
T Cell ◽  
Cytotoxic Activity ◽  
Tumor Cells ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

Differential Expression of the Homeobox Gene MIXL1 in Non Hodgkin (NHL) and Hodgkin Lymphomas (HL).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3014-3014
Author(s):  
Elias Drakos ◽  
George Z. Rassidakis ◽  
Wei Guo ◽  
L. Jeffrey Medeiros ◽  
Lalitha Nagarajan
Keyword(s):  
T Cell ◽  
Protein Expression ◽  
B Cell ◽  
Tumor Cells ◽  
Cell Lymphoma ◽  
Lymphoblastic Leukemia ◽  
T Cell Lymphoma ◽  
High Grade ◽  
Intermediate Grade ◽  
Aberrant Expression

Abstract The gene MIXL1 (Mix1 homeobox-like) encodes a paired class homeobox transcription factor involved in early hematopoietic specification during embryogenesis. Previous studies have shown that MIXL1 gene is expressed in hematopoietic cells during adult life (Guo et al. Blood100;1;89–96, 2002). Furthermore 5′ MIXL1 sequences are a target of retroviral insertion in murine T-cell lymphoma (http:RTCGD.ncifcrf.gov), suggesting a selection advantage for aberrant expression of this gene. However, the status of MIXL1 expression in human lymphomas has not been examined. Using a highly specific antibody, we assessed for MIXL1 protein expression in 14 lymphoma cell lines (9 B-cell and 5 T-cell) by immunobloting. MIXL1 was detected predominantly in nuclear extracts of lysates of all cell lines tested, although at a variable level. We also assessed for MIXL1 protein expression in 126 B-cell and 21 T-cell NHLs of various types, as well as 14 Hodgkin lymphomas using immunohistochemical methods. The results of the immunohistochemical studies are summarized in table 1. Once again, MIXL1 immunoreactivity was primarily nuclear in the tumor cells. Based on distribution data (histogram), a 50% cutoff was selected for high versus low MIXL1 expression. Among B-cell tumors, high expression levels of MIXL1 protein were more frequently detected in high-grade NHL and HL compared with low/intermediate grade NHL (p<0.0001, chi-square test). As a continuous variable, the percentage of MIXL1-positive tumor cells was also significantly higher in high-grade B-cell NHL and HL compared with low/intermediate grade NHL (p<0.0001, Kruskal Wallis test). All Hodgkin lymphomas expressed high levels of MIXL1 with 60% to 100% of neoplastic cells being positive for MIXL1. Most T-cell NHLs also expressed high levels of MIXL1. In contrast, most low/intermediate-grade B-cell NHL and multiple myelomas expressed low levels of MIXL1. Frequent overexpression of MIXL1 gene product in most high-grade B-cell NHLs, HL and T-cell NHLs suggests that aberrant expression of MIXL1 may play a role in proliferation, block of differentiation or both. Table 1. HL (n=14) B-NHL (n =126) T-NHL (n =21) N (%) Low/intermediate grade N (%) N (%) Classical HL 12/12(100%) Chronic lymphocytic leukemia /small lymphocytic lymphoma 0/8 (0% T-precursor lymphoblastic leukemia/lymphoma 2/2 (0%) Nodular lymphocyte predominance HL 2/2 (100%) MALT-lymphoma 0/8 (0%) Mycosis fungoides/Sezary syndrome 2/2 (0%) Follicular lymphoma 9/24 (38%) Extranodal NK/T-cell lymphoma, nasal type 3/3 (100%) Mantle cell lymphoma 5/34 (15%) Peripheral T-cell lymphoma, unspecified 6/9 (66% High grade Anaplastic large cell lymphoma 5/5 (100%) B-precursor lymphoblastic leukemia/lymphoma 1/3 (33%) Burkitt lymphoma/leukemia 2/2 (100%) Diffuse large B-cell lymphoma 30/31 (97%) Plasma cell myeloma/plasmacytoma 0/16 (0%)

scholarly journals Primary Extra Nodal NK/T Cell Lymphoma in the Gallbladder: A Rare Case Report

2021 ◽  
Author(s):  
Ya Jiang ◽  
Shi-Yi Long ◽  
Wen-Mang Xu ◽  
Zi-Ran Gao ◽  
Xin-Yan Pan ◽  
...  
Keyword(s):  
T Cell ◽  
Tumor Cells ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Submucosal Tumor ◽  
Gallbladder Wall ◽  
T Cell Lymphoma ◽  
High Signal ◽  
Nk T Cell ◽  
The Right

Abstract Background Extra nodal NK/T cell lymphoma (ENKTL) is rarely occurred in the gallbladder, and it is generally difficult to diagnose before surgery. Here we present a case of primary ENKTL of gallbladder. Case presentation A 61-year-old female with pain in the right upper abdomen, and Murphy's sign was positive. Ultrasonography showed that a submucosal tumor-like lesion in the neck of the gallbladder, and the gallbladder wall thickness was 0.6cm; there were several high-signal stone shadows. Microscopic examination revealed coagulative necrosis in the lamina propria of the mucosa, the tumor cells were grown diffusely infiltrating, which with medium to large size and inconspicuous or small nucleoli. Immunohistochemistry showed that the tumor cells were positively expressed CD3, CD2, CD56, CD43, TIA-1, Perforin, Granzyme-B, and EBER-ISH (-). Based on these findings, the pathological diagnosis was ENKTL of the gallbladder. The patient received CHOP chemotherapy regimens, who has been free of recurrence for 8 months after the surgery. Conclusion In the early stage, histological diagnosis of ENKTL is difficult, and the patient may not have obvious symptoms, for patients with the gallbladder wall thickens and has protrusions, ENKTL should be regarded as one of the differential diagnosis.

scholarly journals Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

2021 ◽  
Author(s):  
Garry Nolan ◽  
Darci Phillips ◽  
Magdalena Matusiak ◽  
Belén Gutierrez ◽  
Salil Bhate ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Clinical Response ◽  
Tumor Cells ◽  
Cd4 T Cells ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
T Cell Subsets ◽  
Cutaneous T Cell Lymphoma

Abstract Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T cell lymphoma (CTCL) patients enrolled in a clinical trial of pembrolizumab therapy. Clinical response was not associated with the frequency of tumor-infiltrating T cell subsets, but rather with striking differences in the spatial organization and functional immune state of the tumor microenvironment (TME). After treatment, pembrolizumab responders had a localized enrichment of tumor and CD4+ T cells, which coincided with immune activation and cytotoxic PD-1+ CD4+ T cells. In contrast, non-responders had a localized enrichment of Tregs pre- and post-treatment, consistent with a persistently immunosuppressed TME and exhausted PD-1+ CD4+ T cells. Integrating these findings by computing the physical distances between PD-1+ CD4+ T cells, tumor cells, and Tregs revealed a spatial biomarker predictive of pembrolizumab response. Finally, the chemokine CXCL13 was upregulated in tumor cells in responders post-treatment, suggesting that chemoattraction of PD-1+ CD4+ T cells towards tumor cells facilitates a positive outcome. Together, these data show that T cell topography reflects the balance of effector and suppressive activity within the TME and predicts clinical response to PD-1 blockade in CTCL.

Sign in / Sign up

Export Citation Format

Share Document